Alaunos Therapeutics, Inc. Contract Revenue Cost (Deprecated 2018-01-31)
Alaunos Therapeutics, Inc. (TCRT) reported Contract Revenue Cost (Deprecated 2018-01-31) of $10.67 million for the 3-month period ending 2011-09-30, per its 10-Q filed 2011-11-03.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ContractRevenueCost · last filed 2011-11-03
- Alaunos Therapeutics, Inc. contract revenue cost (deprecated 2018-01-31) for the quarter ending 2011-09-30 was $10.67M, a 86.78% increase year-over-year.
- Alaunos Therapeutics, Inc. contract revenue cost (deprecated 2018-01-31) for the quarter ending 2011-06-30 was $9.13M, a 310.67% increase year-over-year.
- Alaunos Therapeutics, Inc. contract revenue cost (deprecated 2018-01-31) for the quarter ending 2010-09-30 was $5.71M, a 363.93% increase year-over-year.
- Alaunos Therapeutics, Inc. contract revenue cost (deprecated 2018-01-31) for the quarter ending 2010-06-30 was $2.22M.
| Period end | Contract Revenue Cost (Deprecated 2018-01-31) 3 month | Contract Revenue Cost (Deprecated 2018-01-31) 6 month | Contract Revenue Cost (Deprecated 2018-01-31) 9 month | Contract Revenue Cost (Deprecated 2018-01-31) 85 month | Contract Revenue Cost (Deprecated 2018-01-31) 94 month | Contract Revenue Cost (Deprecated 2018-01-31) 97 month |
|---|---|---|---|---|---|---|
| 2011-09-30 | $10.67M 10-Q · filed 2011-11-03 | $19.79M derived: sum of 2 quarters · filed 2011-11-03 | $44.43M 10-Q · filed 2011-11-03 | $116.25M 10-Q · filed 2011-11-03 | ||
| 2011-06-30 | $9.13M 10-Q/A · filed 2011-08-09 | $33.77M 10-Q/A · filed 2011-08-09 | $105.58M 10-Q/A · filed 2011-08-09 | |||
| 2010-09-30 | $5.71M 10-Q · filed 2011-11-03 | $7.93M derived: sum of 2 quarters · filed 2011-11-03 | $9.87M 10-Q · filed 2011-11-03 | $68.78M 10-Q · filed 2011-08-01 | ||
| 2010-06-30 | $2.22M 10-Q/A · filed 2011-08-09 | $4.16M 10-Q/A · filed 2011-08-09 | ||||
| 2009-09-30 | $1.23M 10-Q · filed 2011-08-01 | $3.34M 10-Q · filed 2011-08-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |